The total industrial output value of Yunnan biopharmaceutical industry is 46.5 billion yuan

At the opening ceremony of the National Pharmacy Week and the 13th Annual Meeting of China Pharmaceutical Industry 100 held on July 4, Zhu Wenchen, Chairman of Furen Pharmaceutical Group Co., Ltd., said in a speech on behalf of the Top 100 Industrial Enterprises that the National Pharmacy Week and China Pharmaceutical Industry Top 100 Annual Meeting will continue to empower the development of China's pharmaceutical industry.
opening ceremony, more than 100 biopharmaceutical enterprises across the country launched the main products and new research and development of new pharmaceutical products. "Supor Nanyang Pharmaceuticals has set up an office in Kunming, the next step will be to focus on investment and development to Kunming, because Kunming's large health industry and biopharmaceutical industry development prospects are very broad, worthy of investment." In
years, with the rapid development of Yunnan Province, Kunming city's large health industry and biopharmaceutical industry, many well-known enterprises at home and abroad have entered, the big health industry has gradually become Another new business card in Kunming. Yunnan Provincial Committee, provincial government, Kunming Municipal Committee, the municipal government issued a series of incentives, support preferential policies, expanding the size of the pharmaceutical and medical services market, for the transformation of resources, industrial upgrading, rapid development of trade and commerce provides a good opportunity, so that the development prospects of the biopharmaceutical industry is more and more broad.
In recent years, Yunnan's biopharmaceutical industry structure and enterprise transformation and upgrading have been deepening, basically forming an industrial system consisting of traditional Chinese medicine cultivation and processing, research and development and production of biomedical-grade health products, medical and health services, trade and circulation, etc., focusing on natural medicine (Chinese medicine). Next, Yunnan will actively promote reform measures such as management services, innovate regulatory methods, enhance regulatory effectiveness, strengthen service guidance, promote cross-regional, cross-ownership, cross-enterprise merger and reorganization, encourage the development of modern logistics of pharmaceuticals and Internet-plus medicine, continuously improve the innovation and development capacity of Yunnan's pharmaceutical and medical services industry, better service health Yunnan construction, and comprehensively promote Yunnan's pharmaceutical industry to a new level.according to
, there are 215 existing pharmaceutical production enterprises in Yunnan, with a total industrial output value of 46.5 billion yuan in 2017, with an output value of more than 1 billion yuan, and 8 pharmaceutical wholesale enterprises, 19106 retail pharmacies, nearly half of which are chain pharmacies, with sales of 77.7 billion yuan in 2017.
latest data from the Southern Pharmaceutical Economics Research Institute show that in 2017, China's top 100 pharmaceutical industry enterprises generated 138.5 billion yuan of main business income, accounting for 47.8% of China's pharmaceutical industry sales revenue. Among them, six of the top 10 companies exceeded 20 billion yuan, the market concentration of these six enterprises reached 16%, the size of 10 billion yuan to 20 billion yuan of enterprise market concentration reached 11.7%. There are six new companies on the list in 2017, all of which are among the "1.5 billion plus" clubs. In 2017, the average sales revenue growth rate of the top 100 pharmaceutical companies reached 12.8%, 1.4 percentage points faster than the overall growth rate of the pharmaceutical industry. Among them, the top 20 growth drug companies in the list, the average growth rate of 15.9%, is a growth force. It is not difficult to see from this set of data, just unveiled the hundred compulsory pharmaceutical industry represents the new era of China's pharmaceutical industry power.
the top 12 lists, 80% of corporate names remain on the list. How can mainstream pharmaceutical enterprises maintain their vitality and flourish? One of the important reasons is innovation. Manufacturing industry, as the cornerstone of China's pharmaceutical industry, can only respond to the war in trade with innovation as the first productive force. Chinese medicine has been actively integrated into the re-structure of the global research and development value chain, from laboratory to clinical research, from research and development outsourcing to contract manufacturing, from early incubation of capital to global simultaneous listing, and an innovative ecosystem of multi-power convergence is taking shape. In the policy intensive out, the pharmaceutical industry after a new change, the pharmaceutical industry's top 100 show the spirit of innovation, it is the precious spiritual wealth of this era, leading the industry to achieve transformation and upgrading. (Kunming Daily)